Abstract

This anti-aging agent contains, as an active ingredient, a compound represented by formula (I), a racemate thereof, or a salt thereof. (In formula (I), a carbon atom in a glycerol skeleton may have a substituent, an oxygen atom bound to R1is represented by *, and R1 is a compound that may have a substituent.)

IPC Classes  ?

• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A muscle enhancing agent according to the present invention contains a plasmalogen as an active ingredient.

IPC Classes  ?

• A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61K 35/57 - BirdsMaterials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
• A61K 35/618 - Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
• A61K 35/655 - Aquatic animals other than those covered by groups
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A compound represented by formula (I), its racemic form, or their salt, wherein X represents an oxygen atom, a nitrogen atom or a sulfur atom; R1 represents an unsaturated aliphatic hydrocarbon group; R2 represents a saturated or unsaturated aliphatic hydrocarbon group; and R3 represents choline, ethanolamine, inositol or serine. A compound represented by formula (I), its racemic form, or their salt, wherein X represents an oxygen atom, a nitrogen atom or a sulfur atom; R1 represents an unsaturated aliphatic hydrocarbon group; R2 represents a saturated or unsaturated aliphatic hydrocarbon group; and R3 represents choline, ethanolamine, inositol or serine.

IPC Classes  ?

• C07F 9/10 - Phosphatides, e.g. lecithin
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

This agent for increasing brain plasmalogen contains a compound represented by formula (I), a racemic body thereof, or a salt of those. [In formula (I), X represents a carbon atom or an oxygen atom, R1represents a saturated aliphatic hydrocarbon group optionally containing a cyclic structure, and R2 represents a C10-30 saturated or unsaturated aliphatic hydrocarbon group optionally having a C1-4 alkyl group or a C1-4 alkoxy group as a substitution group.]

IPC Classes  ?

• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A composition for ameliorating periodontal tissue containing plasmalogen extracted from animal tissues such as shellfish, sea squirts and birds.

IPC Classes  ?

• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Abstract

A plasmalogen production–promoting culture medium according to the present invention includes lactose as a carbon source and is to be used to culture lactic acid bacteria.

IPC Classes  ?

• C12P 9/00 - Preparation of organic compounds containing a metal or atom other than H, N, C, O, S, or halogen
• C12N 1/20 - BacteriaCulture media therefor
• C12P 7/6427 - Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone

Abstract

This protein comprises an amino acid sequence selected from the group consisting of amino acid sequences (a), (b), (c) and (d) and has a plasmalogen synthesis activity in a bacterium that expresses the protein. (a) The amino acid sequence represented by SEQ ID NO:1; (b) an amino acid sequence which has 80% or higher sequence identity with the amino acid sequence represented by SEQ ID NO:1; (c) the amino acid sequence represented by SEQ ID NO:2; and (d) an amino acid sequence which has 80% or higher sequence identity with the amino acid sequence represented by SEQ ID NO:2.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats

Abstract

This disease state assessment kit for Rett syndrome comprises a reagent for detecting a gene contained in the mitochondrial genome in a sample collected from a subject.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/6813 - Hybridisation assays
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

A composition for ameliorating skin condition having a collagen production promoting effect, a composition for ameliorating skin resilience, a composition for ameliorating skin wrinkles, a composition for ameliorating skin sagging, and a composition for promoting collagen production.

IPC Classes  ?

• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
• A61Q 19/08 - Anti-ageing preparations
• A61Q 19/00 - Preparations for care of the skin

Abstract

This lactic acid bacterium for synthesizing a plasmalogen synthesizes a plasmalogen under an aerobic condition.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12P 9/00 - Preparation of organic compounds containing a metal or atom other than H, N, C, O, S, or halogen

Abstract

This anticancer drug contains an ATP8B2 inhibitor.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61P 35/00 - Antineoplastic agents
• C12Q 1/06 - Quantitative determination
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A composition having hair growth and/hair restoration effect that includes plasmalogen extracted from tissues of animal such as shellfish, sea squirt, and birds, and that can be used as external preparation or oral preparation.

IPC Classes  ?

• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
• A61Q 7/00 - Preparations for affecting hair growth

Abstract

This compound is represented by formula (I). (In formula (I), a carbon atom in the glycerol backbone may have a substituent; an oxygen atom bound to R1is represented by *; and R1 is formula (I-1) which may have a substituent.)

IPC Classes  ?

• C07F 9/10 - Phosphatides, e.g. lecithin
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

It is a composition for enhancing immune function, or a composition for activating natural killer cells, comprising plasmalogen.

IPC Classes  ?

• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61P 37/04 - Immunostimulants
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• A61P 31/04 - Antibacterial agents

Abstract

The present invention provides a novel compound which exhibits an excellent anti-inflammatory effect and which is formed from a compound represented by general formula (I), a racemate thereof, or salts of the compound and the racemate. (In general formula (I), X represents an oxygen atom, a nitrogen atom, or a sulfur atom; R1represents an unsaturated aliphatic hydrocarbon group; R2represents a saturated or unsaturated aliphatic hydrocarbon group; and R3 represents choline, ethanolamine, inositol, or serine.)

IPC Classes  ?

• C07F 9/09 - Esters of phosphoric acids
• C07F 9/10 - Phosphatides, e.g. lecithin
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The purpose of the present invention is to improve periodontal inflammation. It is possible to improve periodontal inflammation by using a periodontal inflammation improving composition that contains plasmalogen extracted from a tissue of an animal such as shellfish, ascidians, and aves.

IPC Classes  ?

• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61K 31/688 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses

Abstract

Provided are: a composition for improving skin, the composition having an excellent effect of promoting collagen generation; a composition for improving skin elasticity; a composition for reducing wrinkles of skin; a composition for mitigating drooping skin; and a composition for promoting collagen generation.

IPC Classes  ?

• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 17/00 - Drugs for dermatological disorders
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/08 - Anti-ageing preparations
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• C12N 15/12 - Genes encoding animal proteins
• A61K 35/57 - BirdsMaterials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
• A61K 35/618 - Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
• A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols

Abstract

Provided is a composition that contains plasmalogen extracted from the tissue of an animal such as a shellfish, ascidian, bird, and so forth, and that exhibits an excellent hair growth and/or hair restoration activity. The composition can be used as a topical agent or an oral agent.

IPC Classes  ?

• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61Q 7/00 - Preparations for affecting hair growth
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• A61K 35/57 - BirdsMaterials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
• A61K 35/616 - Echinodermata, e.g. starfish, sea cucumbers or sea urchins
• A61K 35/618 - Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin

Abstract

An immune function enhancing composition or a natural killer cell activation composition characterized by containing plasmalogen.

IPC Classes  ?

• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 35/57 - BirdsMaterials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
• A61K 35/618 - Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
• A61P 31/04 - Antibacterial agents
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

[Problem] To provide a method for producing a high-purity ether-type glycerophospholipid with high efficiency by a simple procedure. [Solution] This production method comprises treating a biological material or a tissue thereof with a protease to lyse the tissue of the biological material and, simultaneously with or subsequent to the treatment with the protease, treating the lysate with a lipolytic enzyme to hydrolyze a diacyl-type glycerophospholipid contained in the tissue of the biological material. It becomes possible to produce a high-purity ether-type glycerophospholipid with high efficiency by a simple procedure without requiring a primary extraction operation, i.e., the extraction of all of lipids before a treatment with an enzyme, or an operation for removing a neutral lipid from all of the lipids or a re-suspension operation.

IPC Classes  ?

• C12P 9/00 - Preparation of organic compounds containing a metal or atom other than H, N, C, O, S, or halogen
• C07F 9/10 - Phosphatides, e.g. lecithin
• C11B 1/10 - Production of fats or fatty oils from raw materials by extracting
• C11B 7/00 - Separation of mixtures of fats or fatty oils into their constituents, e.g. saturated oils from unsaturated oils
• C12P 13/00 - Preparation of nitrogen-containing organic compounds

Abstract

Provided is a novel hair growth and hair restoration material having excellent efficacy in hair growth and hair restoration for both men and women, even when the components thereof are at ultra-dilute concentrations; the hair growth and hair restoration material being characterized in containing a sterol glucopyranoside, preferably a cholesteryl glucopyranoside, represented by general formula (I). (In the formula, Z represents a sterol residue from which the hydroxyl group attached to the 3-position of a cyclopentanohydrophenanthrene ring has been removed.)

IPC Classes  ?

• A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 8/63 - SteroidsDerivatives thereof
• A61Q 7/00 - Preparations for affecting hair growth
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 8/60 - SugarsDerivatives thereof
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin

Abstract

Provided is a novel hair growth and hair restoration material having excellent efficacy in hair growth and hair restoration for both men and women, even when the components thereof are at ultra-dilute concentrations; the hair growth and hair restoration material being characterized in containing a steryl glucopyranoside, preferably a cholesteryl glucopyranoside, represented by general formula (I). (In the formula, Z represents a sterol residue from which the hydroxyl group attached to the 3-position of a cyclopentanohydrophenanthrene ring has been removed.)

IPC Classes  ?

• A61K 8/63 - SteroidsDerivatives thereof
• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61Q 7/00 - Preparations for affecting hair growth

Abstract

A compound produced in tea leaves by fermentation and not found in raw material tea leaves is obtained by fermenting for 3 to 10 days using black rice malt and particularly using second-picking tea as the tea leaves, and used as an active ingredient in medicines for suppressing elevation of the blood sugar level, lowering triglycerides, improving liver function, suppressing elevation of the blood pressure, improving cholesterol metabolism, improving renal function, and the like. In addition to being obtainable from fermented tea leaves, the compound can also be prepared by chemical synthesis, biosynthesis, and the like, once its structure has been identified.

IPC Classes  ?

• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/12 - Antihypertensives
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
• C07D 493/04 - Ortho-condensed systems

Abstract

Disclosed is a method for producing a phospholipid-containing functional material or a high-purity plasmalogen-type glycerophospholipid from a poultry breast meat by a simple manipulation and in high yield. Specifically disclosed are: a method for producing a phospholipid-containing functional material by transforming the shape of a poultry breast meat by at least one process selected from the following processes (a) to (c): (a) a process of mincing the poultry breast meat in a low-temperature and low-oxygen atmosphere; (b) a process of pasting the poultry breast meat together with an emulsifying/dispersing agent at a low temperature; and (c) a process of powderizing the poultry breast meat by drying at a low temperature; and a method for producing a plasmalogen-type glycerophospholipid, which comprises the following steps (A) to (C): (A) extracting the entire fat material from a powder of a poultry breast meat and drying the extracted fat material; (B) extracting the dried entire fat material with a solvent to separate into an insoluble fraction and a soluble fraction; and (C) extracting the soluble fraction with a solvent to separate and collect the insoluble fraction.

IPC Classes  ?

• C11B 11/00 - Recovery or refining of other fatty substances, e.g. lanolin or waxes
• C11B 1/00 - Production of fats or fatty oils from raw materials

Abstract

A process for producing a functional material by deoiling/defatting poultry epidermis via a heating treatment to thereby concentrate and pasteurize a human type sphingomyelin and a plasmalogen type glycerophospholipid contained in the epidermis, characterized in that the heating treatment comprises: (A) the step wherein hot water and/or steam having been heated to 100oC or higher is continuously jetted into a heating chamber that is a semi-closed space having been heated to the same temperature or higher to thereby generate water droplets and hot and wet steam; (B) the step wherein the atmosphere in the above-described heating chamber is replaced by the water droplets and hot and wet steam as described above so as to fill the chamber with a gas component (gaseous water) which has a relative humidity of 95% or higher and an oxygen concentration of 0.2% by volume or less and is maintained within a temperature range of from 100 to 115oC; (C) the step wherein 100%-moistened steam is jetted to the above-described gaseous water so as to stably form a composite heating medium which comprises the hot water, water droplets and steam; and (D) the step wherein the poultry epidermis is subjected to the heat treatment by conducting continuous amplitude heating of a temperature difference of at least 10oC with the above-described composite heating medium in an atmosphere at a temperature of 100 to 115oC and an oxygen concentration of 0.2% by volume or less.

IPC Classes  ?

• A23J 7/00 - Phosphatide compositions for foodstuffs, e.g. lecithin
• A23L 1/30 - containing additives (A23L 1/308 takes precedence);;
• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
• A61K 8/68 - Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
• A61Q 19/00 - Preparations for care of the skin

Abstract

A process for producing sphingomyelin and plasmalogen-form glycerophospholipid, characterized by comprising:(A) a step in which all lipids are extracted from a chicken-skin powder and dried; (B) a step in which the dried all lipids obtained in the step (A) are extracted with a solvent mixture of an aliphatic hydrocarbon solvent and a water-soluble ketone solvent to separate the lipids into an insoluble part consisting mainly of sphingomyelin and a soluble part; (C) a step in which the insoluble part consisting mainly of sphingomyelin obtained in the step (B) is extracted with a solvent mixture of water and a water-soluble ketone solvent to remove the non-lipid ingredients from the soluble part; and (D) a step in which the soluble part obtained in the step (B) is dried and then extracted with a water-soluble ketone solvent to separate and recover an insoluble part consisting mainly of a plasmalogen-form glycerophospholipid. Thus, high-purity sphingomyelin, especially human sphingomyelin, and a plasmalogen-form glycerophospholipid can be produced in a satisfactory yield from the skin of a chicken by a simple operation.

IPC Classes  ?

• C11B 1/10 - Production of fats or fatty oils from raw materials by extracting